BTIG Research started coverage on shares of Organogenesis (NASDAQ:ORGO) in a report released on Friday morning, AnalystRatings.com reports. The firm issued a buy rating and a $12.00 price objective on the stock.
“Improved Cap Structure, ORGO $12 PT Organogenesis (ORGO) has been in the wound market since 1998, creating one of the largest pure-play wound care companies in the fast growing and underpenetrated Advanced Wound Care market. ORGO has built a ~$200M rev. business driven by a combo of stalwart wound products (Apligraf and Dermagraft) with faster growing PuraPly for early wound intervention. With an expansive portfolio and a significantly under- penetrated market opportunity (plus additional TAM outside of wound), ORGO has runway to grow. In addition, ORGO may be able to capture share from embattled competitors who may be struggling. Lastly, while reimbursement changes may hamper growth in one of ORGO’s products in late FY20, the combination of NPIs, a growing sales force, and clinical efficacy should mitigate reimbursement headwinds.”,” the firm’s analyst commented.
Separately, SunTrust Banks initiated coverage on shares of Organogenesis in a research report on Thursday, April 11th. They issued a buy rating and a $11.00 target price for the company.
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Featured Article: Do closed-end mutual funds pay dividends?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.